Fosun Pharma’s 24-valent pneumococcal vaccine clinical trial approved
March 6, 2025
Source: drugdu
90
On the evening of March 4, Fosun Pharma (600196) issued an announcement stating that the company's holding subsidiary Fosun Antekin (Chengdu) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Fosun Antekin") recently received approval from the National Medical Products Administration for clinical trials of 24-valent pneumococcal polysaccharide conjugate vaccine (application registration classification: preventive biological products 1.4; hereinafter referred to as "24-valent pneumococcal vaccine"). Fosun Antekin intends to conduct Phase I clinical trials of the vaccine in China (excluding Hong Kong, Macao and Taiwan) when conditions are met.
https://finance.eastmoney.com/a/202503043336146495.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Merck’s 9-valent HPV vaccine has been approved for marketing in men; New Hecheng’s net profit increased by 117.01% year-on-year | April 16, 2025
- Intravenous human immunoglobulin (IVIG) is in the drug approval stage April 16, 2025
- Implement penetrating supervision on medical institutions’ practices, drug and equipment circulation, and medical insurance fund use April 16, 2025
- Tianyu shares wholly-owned subsidiary obtains drug registration certificate for pravastatin sodium tablets April 16, 2025
- The nine-valent HPV vaccine for men is now available April 16, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
